BR0212020A - Dosage forms, methods for preventing abuse of a dosage form, methods for preventing diversion of a dosage form, methods for treating pain and method of preparing a dosage form - Google Patents
Dosage forms, methods for preventing abuse of a dosage form, methods for preventing diversion of a dosage form, methods for treating pain and method of preparing a dosage formInfo
- Publication number
- BR0212020A BR0212020A BR0212020-8A BR0212020A BR0212020A BR 0212020 A BR0212020 A BR 0212020A BR 0212020 A BR0212020 A BR 0212020A BR 0212020 A BR0212020 A BR 0212020A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- dosage form
- preventing
- dosage
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"FORMAS DE DOSAGEM, MéTODOS PARA IMPEDIR O ABUSO DE UMA FORMA DE DOSAGEM, MéTODOS PARA IMPEDIR O DESVIO DE UMA FORMA DE DOSAGEM, MéTODOS PARA O TRATAMENTO DE DOR E MéTODO DE PREPARAçãO DE UMA FORMA DE DOSAGEM". Trata-se de métodos e composições para impedir o abuso de formas de dosagem que compreendem um analgésico de opióide ou uma outra droga que possa ser o objeto de abuso, e pelo menos um agente aversivo em uma quantidade eficaz para impedir que um usuário em abuso administre uma forma alterada da dita forma de dosagem intravenosamente, intranasalmente, e/ou oralmente."DOSAGE FORMS, METHODS TO PREVENT ABUSE OF A DOSAGE FORM, METHODS TO PREVENT DEVIATION OF A DOSAGE FORM, METHODS FOR PAIN TREATMENT AND METHOD FOR PREPARING A DOSAGE FORM". These are methods and compositions for preventing abuse of dosage forms comprising an opioid analgesic or other drug that may be abused, and at least one aversive agent in an amount effective to prevent an abusive user. administer an altered form of said dosage form intravenously, intranasally, and / or orally.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31053501P | 2001-08-06 | 2001-08-06 | |
US31051401P | 2001-08-06 | 2001-08-06 | |
US31053401P | 2001-08-06 | 2001-08-06 | |
PCT/US2002/024935 WO2003013476A1 (en) | 2001-08-06 | 2002-08-06 | Compositions and methods to prevent abuse of opioids |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0212020A true BR0212020A (en) | 2005-08-16 |
Family
ID=27405461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0212020-8A BR0212020A (en) | 2001-08-06 | 2002-08-06 | Dosage forms, methods for preventing abuse of a dosage form, methods for preventing diversion of a dosage form, methods for treating pain and method of preparing a dosage form |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1414413A1 (en) |
JP (1) | JP2005500364A (en) |
KR (1) | KR20040025741A (en) |
BR (1) | BR0212020A (en) |
CA (1) | CA2455420A1 (en) |
DE (1) | DE20220917U1 (en) |
HU (1) | HUP0401344A2 (en) |
IL (1) | IL160217A0 (en) |
MX (1) | MXPA04001206A (en) |
WO (1) | WO2003013476A1 (en) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
PT1041987E (en) | 1997-12-22 | 2006-07-31 | Euro Celtique Sa | PHARMACEUTICAL FORM OF ORAL DOSAGE, UNDERSTANDING A COMBINATION OF AN AGRONIST OF OPIOIDE AND NALTREXONE |
EP1387673B1 (en) | 2001-05-11 | 2010-12-29 | Endo Pharmaceuticals Inc. | Abuse-resistant controlled-release opioid dosage form |
US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
CN1268338C (en) | 2001-07-06 | 2006-08-09 | 恩德制药公司 | Oral administration of 6-hydroxy-oxymorphone for use as antalgesic |
US20030068276A1 (en) | 2001-09-17 | 2003-04-10 | Lyn Hughes | Dosage forms |
ES2733051T1 (en) | 2002-04-05 | 2019-11-27 | Euro Celtique Sa | Matrix for sustained, invariable and independent release of active compounds |
ATE419840T1 (en) | 2002-04-09 | 2009-01-15 | Flamel Tech Sa | ORAL AQUEOUS SUSPENSION CONTAINING MICROCAPSULES FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE10250083A1 (en) * | 2002-06-17 | 2003-12-24 | Gruenenthal Gmbh | Dosage form protected against abuse |
DK1551372T3 (en) * | 2002-09-20 | 2018-07-23 | Alpharma Pharmaceuticals Llc | SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES |
DE10250084A1 (en) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Dosage form protected against abuse |
PT2218448E (en) | 2002-12-13 | 2016-01-26 | Durect Corp | Oral drug delivery system comprising high viscosity liquid carrier materials |
EP1782834A3 (en) * | 2003-03-13 | 2007-08-01 | Controlled Chemicals, Inc. | Oxycodone conjugates with lower abuse potential and extended duration of action |
US8906413B2 (en) * | 2003-05-12 | 2014-12-09 | Supernus Pharmaceuticals, Inc. | Drug formulations having reduced abuse potential |
WO2004112756A1 (en) | 2003-06-26 | 2004-12-29 | Isa Odidi | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102004032051A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
PT1658054E (en) * | 2003-08-06 | 2007-09-18 | Gruenenthal Gmbh | Dosage form that is safeguarded from abuse |
WO2005034859A2 (en) * | 2003-10-03 | 2005-04-21 | Elite Laboratories Inc. | Extended release formulations of opioids and method of use thereof |
US20050163718A1 (en) * | 2004-01-23 | 2005-07-28 | Shugart Jack I. | Injectable euthanasia compositions that include a taste aversive agent |
GB0501638D0 (en) * | 2005-01-28 | 2005-03-02 | Euro Celtique Sa | Particulates |
DE102004019916A1 (en) * | 2004-04-21 | 2005-11-17 | Grünenthal GmbH | Anti-abuse drug-containing patch |
EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
ITMI20041317A1 (en) * | 2004-06-30 | 2004-09-30 | Ibsa Inst Biochimique Sa | PHARMACEUTICAL FORMULATIONS FOR THE SAFE ADMINISTRATION OF DRUGS USED IN THE TREATMENT OF DRUG ADDICTION AND PROCEDURE FOR THEIR OBTAINING |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
FR2878161B1 (en) * | 2004-11-23 | 2008-10-31 | Flamel Technologies Sa | ORAL MEDICINE FORM, SOLID AND DESIGNED TO AVOID MEASUREMENT |
GEP20105052B (en) * | 2005-01-28 | 2010-07-26 | Euro Celtique Sa | Alcohol resistant dosage forms |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
FR2889810A1 (en) * | 2005-05-24 | 2007-02-23 | Flamel Technologies Sa | ORAL MEDICINAL FORM, MICROPARTICULAR, ANTI-MEASUREMENT |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
FR2892937B1 (en) * | 2005-11-10 | 2013-04-05 | Flamel Tech Sa | MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
CA2648280C (en) | 2006-04-03 | 2014-03-11 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
US9023400B2 (en) | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
FR2901478B1 (en) * | 2006-05-24 | 2015-06-05 | Flamel Tech Sa | MULTIMICROPARTICULATED ORAL PHARMACEUTICAL FORM WITH PROLONGED RELEASE |
US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
WO2008051889A1 (en) * | 2006-10-24 | 2008-05-02 | The Johns Hopkins University | Rapid release mini-tablets provide analgesia in laboratory animals |
EP3326621A1 (en) * | 2007-12-06 | 2018-05-30 | Durect Corporation | Oral pharmaceutical dosage forms |
US8486448B2 (en) | 2007-12-17 | 2013-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
JP5774853B2 (en) | 2008-01-25 | 2015-09-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Pharmaceutical dosage form |
US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
CA2723438C (en) | 2008-05-09 | 2016-10-11 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
JP5667575B2 (en) | 2008-12-16 | 2015-02-12 | パラディン ラブス インコーポレーテッド | Controlled release formulation to prevent misuse |
MY152279A (en) | 2009-03-10 | 2014-09-15 | Euro Celtique Sa | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
MX2012000317A (en) | 2009-07-22 | 2012-02-08 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form. |
MX2012000369A (en) | 2009-07-22 | 2012-02-01 | Gruenenthal Gmbh | Tamper-resistant dosage form for oxidation-sensitive oploids. |
ES2487244T3 (en) | 2010-09-02 | 2014-08-20 | Grünenthal GmbH | Handling resistant dosage form comprising an anionic polymer |
RU2604676C2 (en) | 2010-09-02 | 2016-12-10 | Грюненталь Гмбх | Destruction-resistant dosage form containing an inorganic salt |
WO2012112952A1 (en) * | 2011-02-17 | 2012-08-23 | QRxPharma Ltd. | Technology for preventing abuse of solid dosage forms |
PT2736495T (en) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US20130028972A1 (en) | 2011-07-29 | 2013-01-31 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
JP6110384B2 (en) * | 2011-09-16 | 2017-04-05 | パーデュー ファーマ エルピー | Tamper-resistant pharmaceutical formulation |
FR2983409B1 (en) * | 2011-12-06 | 2013-12-27 | Ethypharm Sa | COMPRESSOR CAPABLE OF COMBATTING INJECTION MISTAKE |
GB201202433D0 (en) | 2012-02-13 | 2012-03-28 | Diurnal Ltd | Controlled drug release |
BR112014019988A8 (en) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | BREAK-RESISTANT DOSAGE FORM COMPRISING A PHARMACOLOGICALLY ACTIVE COMPOUND AND AN ANIONIC POLYMER |
KR101701013B1 (en) * | 2012-03-02 | 2017-01-31 | 로도스 파머시티컬스 엘.피. | Tamper resistant immediate release formulations |
ES2821773T3 (en) * | 2012-03-02 | 2021-04-27 | Rhodes Pharmaceuticals Lp | Tamper resistant immediate release formulations |
JP6282261B2 (en) | 2012-04-18 | 2018-02-21 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Unauthorized use and overdose prevention pharmaceutical dosage forms |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
KR20150059167A (en) * | 2012-07-06 | 2015-05-29 | 에갈렛 리미티드 | Abuse deterrent pharmaceutical compositions for controlled release |
WO2014123899A1 (en) | 2013-02-05 | 2014-08-14 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US10420729B2 (en) | 2013-03-15 | 2019-09-24 | R.P. Scherer Technologies, Llc | Abuse resistant capsule |
US9555113B2 (en) | 2013-03-15 | 2017-01-31 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
CA2907950A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
BR112015029616A2 (en) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | tamper-resistant dosage form with bimodal release profile |
KR20160031526A (en) | 2013-07-12 | 2016-03-22 | 그뤼넨탈 게엠베하 | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
MY183489A (en) | 2013-07-23 | 2021-02-22 | Euro Celtique Sa | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
MX371372B (en) | 2013-11-26 | 2020-01-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling. |
CA2924016A1 (en) * | 2013-12-03 | 2015-06-11 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
CA2947786A1 (en) | 2014-05-12 | 2015-11-19 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising tapentadol |
WO2015181059A1 (en) | 2014-05-26 | 2015-12-03 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
CN107889459A (en) | 2015-04-24 | 2018-04-06 | 格吕伦塔尔有限公司 | Tamper resistant dosage form with release immediately and to solvent-extracted resistance |
AU2016319203A1 (en) | 2015-09-10 | 2018-02-22 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
EP3473246A1 (en) | 2017-10-19 | 2019-04-24 | Capsugel Belgium NV | Immediate release abuse deterrent formulations |
EP3937929A4 (en) * | 2019-03-11 | 2022-12-28 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
KR102666865B1 (en) | 2022-01-25 | 2024-05-20 | 정광선 | rock salt sitz bath |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869097A (en) * | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
-
2002
- 2002-08-06 IL IL16021702A patent/IL160217A0/en unknown
- 2002-08-06 JP JP2003518486A patent/JP2005500364A/en active Pending
- 2002-08-06 WO PCT/US2002/024935 patent/WO2003013476A1/en not_active Application Discontinuation
- 2002-08-06 MX MXPA04001206A patent/MXPA04001206A/en unknown
- 2002-08-06 HU HU0401344A patent/HUP0401344A2/en unknown
- 2002-08-06 KR KR10-2004-7001877A patent/KR20040025741A/en not_active Application Discontinuation
- 2002-08-06 DE DE20220917U patent/DE20220917U1/en not_active Expired - Lifetime
- 2002-08-06 BR BR0212020-8A patent/BR0212020A/en not_active IP Right Cessation
- 2002-08-06 EP EP02752708A patent/EP1414413A1/en not_active Withdrawn
- 2002-08-06 CA CA002455420A patent/CA2455420A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA04001206A (en) | 2004-07-08 |
JP2005500364A (en) | 2005-01-06 |
WO2003013476A1 (en) | 2003-02-20 |
EP1414413A1 (en) | 2004-05-06 |
IL160217A0 (en) | 2004-07-25 |
CA2455420A1 (en) | 2003-02-20 |
DE20220917U1 (en) | 2004-08-19 |
KR20040025741A (en) | 2004-03-25 |
HUP0401344A2 (en) | 2004-11-29 |
WO2003013476B1 (en) | 2003-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0212020A (en) | Dosage forms, methods for preventing abuse of a dosage form, methods for preventing diversion of a dosage form, methods for treating pain and method of preparing a dosage form | |
BR0212019A (en) | Dosage forms, methods for treating pain, methods of preparing a dosage form and methods for preventing abuse of a dosage form. | |
WO2001082914A3 (en) | Topical anesthetic/opioid formulations and uses thereof | |
NZ592039A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
BR0207024A (en) | Fast-acting drug to treat sexual dysfunction | |
NO20014842L (en) | Docet shaft in combination with rhuMAb HER2 for the treatment of cancer | |
CY1107262T1 (en) | TREATMENT OF DEPENDENCE ADDITION | |
BR9812342A (en) | Analgesic, method of effectively treating pain in humans or other mammals, method of reducing the amount of opioid required to treat patients affected by pain and method of reducing the amount of cox-2 inhibitor required for treating patients affected by pain | |
BR0210104A (en) | Selective skin-permeable cyclooxygenase-2 inhibitory composition | |
BRPI0508769A (en) | tamper-resistant dosage form comprising an adsorbent and an adverse agent | |
WO2002058620A3 (en) | Pharmaceutical compositions containing a cox-ii inhibitor and a muscle relaxant | |
BR9812134A (en) | Pharmaceutical composition for the treatment of dysmenorrhea and premature birth | |
Siddiqui et al. | A literature review on the role of chemical sphincterotomy after Milligan–Morgan hemorrhoidectomy | |
SE0002754D0 (en) | New pharmaceutical combination formulation and method of treatment with the combination | |
BR0008402A (en) | Uses of doxepine, doxepine hydrochloride or a metabolite of doxepine or doxepine hydrochloride, and of a tca, pharmaceutical composition, methods to provide an analgesic treatment, and to improve deep localized or internal pain | |
PT1102586E (en) | USE OF GINKGO BILOBA EXTRACTS FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF AMIOTROPHIC LATERAL SCLEROSIS | |
BRPI0406634A (en) | Use of an anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, non-oral pharmaceutical composition, and transdermal delivery device | |
BR0201974A (en) | Pharmaceutical composition for treating sleep disorders | |
WO2001074365A3 (en) | An efficacious dosage regimen of galantamine that reduces side effects | |
BR0306726A (en) | Mixture of drugs with better dissolution rate | |
BR0207866A (en) | Use of flumazenil in the preparation of a drug for the treatment of ***e addiction | |
BR0211855A (en) | Drug and method for treating and improving restorative sleep quality | |
BR0307022A (en) | Method of treating a patient who needs analgesia | |
HUP0402326A2 (en) | Pharmaceutical composition for prevention of addiction in pain management | |
DE60004833D1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING PARACETAMOL AND BUSPIRON WITH ANALGETIC EFFECT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 5A., 6A. E 7A. ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009. |